Mirimus brings RNAi technology to its peak. Discover potent gene knockdown at a single copy integration and dramatically decreased off-target effects-guaranteed! Using our latest shRNA designs expressed within our proprietary miRE scaffold, we guarantee >80–90% knockdown of any gene target.
Mirimus offers shRNA validation services to identify top-performing shRNAs. Using our functional Sensor reporter assay which quantifies single-copy protein knockdown levels (Fellmann, C., et al, 2011). Mol Cell), we identify optimized shRNA sequences for reliable in vivo gene suppression.
Each shRNA receives a score indicative of its performance to silence its endogenous target. All validations are performed at single-copy genomic integration which reduces sequence-dependent and -independent off-target effects (Yuan, T., et al 2014, Cancer Discov).
Due to its versatility and potential, RNA is increasingly gaining importance as a novel therapeutic. Indeed, such molecules are now employed for the development of vaccines, regulation of the gene expression, and creation of aptamers binding specific targets. The Mirimus Therapeutics department aims to harness the power of the RNA interference (RNAi) machinery to develop novel and highly specific treatments to be used in several pathological conditions. Thanks to our broad expertise in RNAi, we are able to generate artificial microRNAs (amiRNAs) with enhanced processing and specificity to precisely target and efficiently silence genes that are known to be detrimental in a given pathology.